TDD Alopecia Pipeline Watch: Enrollment Complete for Equillium’s Phase 2 Study of EQ101 in AA
Equillium, Inc. has completed enrollment of the EQ101 Phase 2 study in alopecia areata, the Company reports. EQ101 is a first-in-class, selective, tri-specific inhibitor of interleukin (IL)-2, IL-9 and IL-15. The study enrolled 36 patients, of which 13, or 36%, had severe alopecia areata. The study remains ongoing, but EQ101 has been well tolerated over the […]